Ionis Pharmaceuticals and Roche announced positive prespecified interim results from the Phase 3 IMAgINATION study evaluating sefaxersen in adults with primary IgA nephropathy. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in proteinuria compared to placebo at 37 weeks, measured by the urine protein-to-creatinine ratio. Sefaxersen is a once-monthly subcutaneous injection targeting complement factor B, with a safety profile consistent with prior data and no new signals identified. The study will continue blinded to assess kidney function changes over two years via estimated glomerular filtration rate at week 105. Ionis Pharmaceuticals operates in the biotechnology industry, developing RNA-targeted medicines for serious diseases.
